Dorocubicel

度洛珂赛

Report date: 2025/09/15 09:51:20

Base Information

Drug NameDorocubicel
Drug Alias NameZemcelproECT-100ECT-001-CBECT-001UM-171
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAnemia, Sickle CellHematologic NeoplasmsMultiple Myeloma +[4] 
Global Approved IndicationsHematologic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/08/25
Country/TerritoryCanadaUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesExcellthera Inc
China Registration ClassN/A

Develop Information

Active CompaniesCordex Biologics International LtdAstellas Pharma IncExcellthera Inc +[4] 
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)
Active IndicationsHematologic NeoplasmsMultiple Myeloma
Inactive IndicationsAnemia, Sickle CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A